Thorens B
Institute of Pharmacology and Toxicology, Lausanne, Switzerland.
Diabete Metab. 1995 Dec;21(5):311-8.
Although glucose is the major regulator of insulin secretion by pancreatic beta cells, its action is modulated by several neural and hormonal stimuli. In particular, hormones secreted by intestinal endocrine cells stimulate glucose-induced insulin secretion very potently after nutrient absorption. These hormones, called gluco-incretins or insulinotropic hormones, are major regulators of postprandial glucose homeostasis. The main gluco-incretins are GIP (gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like polypeptide-1). The secretion of GIP, a 42 amino acid polypeptide secreted by duodenal K cells, is triggered by fat and glucose. GIP stimulation of insulin secretion depends on the presence of specific beta-cell receptors and requires glucose at a concentration at least equal to or higher than the normoglycaemic level of approximately 5 mM. GIP accounts for about 50% of incretin activity, and the rest may be due to GLP-1 which is produced by proteolytic processing of the preproglucagon molecule in intestinal L cells. GLP-1 is the most potent gluco-incretin characterized so far. As with GIP, its stimulatory action requires a specific membrane receptor and normal or elevated glucose concentrations. Contrary to GIP, the incretin effect of GLP-1 is maintained in non-insulin-dependent diabetic patients. This peptide or agonists of its beta-cell receptor could provide new therapeutic tools for the treatment of Type II diabetic hyperglycaemia.
尽管葡萄糖是胰腺β细胞胰岛素分泌的主要调节因子,但其作用受到多种神经和激素刺激的调节。特别是,肠道内分泌细胞分泌的激素在营养物质吸收后能非常有效地刺激葡萄糖诱导的胰岛素分泌。这些激素,称为葡萄糖依赖性促胰岛素多肽或促胰岛素激素,是餐后葡萄糖稳态的主要调节因子。主要的葡萄糖依赖性促胰岛素多肽是GIP(胃抑制多肽或葡萄糖依赖性促胰岛素多肽)和GLP-1(胰高血糖素样肽-1)。GIP是一种由十二指肠K细胞分泌的42个氨基酸的多肽,其分泌由脂肪和葡萄糖触发。GIP对胰岛素分泌的刺激取决于特定β细胞受体的存在,并且需要葡萄糖浓度至少等于或高于约5 mM的正常血糖水平。GIP约占肠促胰岛素活性的50%,其余可能归因于GLP-1,它是由肠L细胞中前胰高血糖素分子的蛋白水解加工产生的。GLP-1是迄今为止表征的最有效的葡萄糖依赖性促胰岛素多肽。与GIP一样,其刺激作用需要特定的膜受体和正常或升高的葡萄糖浓度。与GIP相反,GLP-1的肠促胰岛素作用在非胰岛素依赖型糖尿病患者中得以维持。这种肽或其β细胞受体激动剂可为治疗II型糖尿病高血糖症提供新的治疗工具。